Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

Summary

The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).

Timeline

Start

2024-04-01

Primary completion

2025-08-01

Completion

2026-02-01

Drugs

Indications